Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

2.

Inhibition of human recombinant PKD2 after 10 mins by radiometric assay [Confirmatory]

Source:
ChEMBL
Protein Target:
Polycystin-2; Autosomal dominant polycystic kidney disease type II protein; Polycystic kidney disease 2 protein; Polycystwin; R48321
3.

Inhibition of PKD1 autophosphorylation at Ser916 in human PMA-induced LNCAP cells by Western blotting [Confirmatory]

Source:
ChEMBL
Protein Target:
Serine/threonine-protein kinase D1; Protein kinase C mu type; Protein kinase D; nPKC-D1; nPKC-mu
4.

Inhibition of human recombinant PKD1 after 10 mins by radiometric assay [Confirmatory]

Source:
ChEMBL
Protein Target:
Serine/threonine-protein kinase D1; Protein kinase C mu type; Protein kinase D; nPKC-D1; nPKC-mu
5.

Inhibition of human recombinant CAMK2alpha at < 10 uM after 10 mins by radiometric assay

Source:
ChEMBL
Protein Target:
Calcium/calmodulin-dependent protein kinase type II subunit alpha; CaM kinase II subunit alpha; CaMK-II subunit alpha
6.

Inhibition of human recombinant PKCdelta at < 10 uM after 10 mins by radiometric assay

Source:
ChEMBL
Protein Target:
Protein kinase C delta type; Tyrosine-protein kinase PRKCD; nPKC-delta; Protein kinase C delta type regulatory subunit; Protein kinase C delta type catalytic subunit; Sphingosine-dependent protein kinase-1; SDK1
7.

Inhibition of human recombinant PKCbeta1 at < 10 uM after 10 mins by radiometric assay

Source:
ChEMBL
Protein Target:
Protein kinase C beta type; PKC-B; PKC-beta
8.

Inhibition of human recombinant PKCalpha at < 10 uM after 10 mins by radiometric assay

Source:
ChEMBL
Protein Target:
Protein kinase C alpha type; PKC-A; PKC-alpha
9.
10.
11.
12.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Refine your results

• What's this?

Actions on your results

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk